Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peptic Ulcers Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00321737
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
80
States / cities
Huntsville, Alabama • Tuscon, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

NCT00367211
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole)
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Jul 23, 2026, 5:45 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational

Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)

NCT00212225
View directory record Official record
Conditions
Helicobacter Infections, Gastritis, Peptic Ulcer
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

NCT00441727
View directory record Official record
Conditions
Gastric Ulcer, Duodenal Ulcer
Interventions
Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
55
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational

H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department

NCT01376414
View directory record Official record
Conditions
Gastritis, Peptic Ulcer, Peptic Ulcer Perforation, Stomach Ulcer
Interventions
Urea Breath Test (UBT) for H. pylori infection
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT00454363
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor
Interventions
Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial

NCT05085405
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding
Interventions
Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation, Clinician Notification with Nurse Facilitation / Patient Activation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

NCT00325715
View directory record Official record
Conditions
Peptic Ulcer
Interventions
AGN 201904, esomeprazole
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT04724291
View directory record Official record
Conditions
Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions
MAGNET
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

NCT03060746
View directory record Official record
Conditions
Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain, Weight Loss, Stomach Ulcer, Loss of Appetite, Bloating
Interventions
Newly Diagnosed
Other
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
22 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Mesa, Arizona • Mission Hills, California • Oxnard, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Jul 23, 2026, 5:45 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

NCT00594854
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PN400 (VIMOVO), Diclofenac/Misoprostol
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational

Treatment of Zollinger-Ellison Syndrome

NCT00001241
View directory record Official record
Conditions
Zollinger Ellison Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

NCT00961350
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PA32540, EC Aspirin 325
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas

NCT00001165
View directory record Official record
Conditions
Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
Interventions
combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Results available

Ulcer Prevention Study in Post Gastric Bypass Patients

NCT00557349
View directory record Official record
Conditions
Marginal Ulcers
Interventions
Omeprazole, Famotidine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 4 Interventional

Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer

NCT00239551
View directory record Official record
Conditions
Stomach Ulcer
Interventions
Prevacid
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

NCT00284908
View directory record Official record
Conditions
Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions
S-Tenatoprazole-Na (STU-Na)
Drug
Lead sponsor
STEBA France
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2008 · Synced Jul 23, 2026, 5:45 AM EDT
Not yet recruiting Not applicable Interventional

Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD

NCT07178821
View directory record Official record
Conditions
Achalasia, Esophageal, GERD (Gastroesophageal Reflux Disease)
Interventions
Conventional POEM, Sling Fiber-Preserving POEM
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus

NCT01080326
View directory record Official record
Conditions
Peptic Ulcer
Interventions
Endoscopic Translumenal Omental Patch
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jul 23, 2026, 5:45 AM EDT
Recruiting Phase 4 Interventional

OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers

NCT05799105
View directory record Official record
Conditions
Marginal Ulcer
Interventions
Omeprazole 40 milligrams
Drug
Lead sponsor
Stephen Firkins
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational

Chronic Marginal Ulcers After Gastric Bypass

NCT01041079
View directory record Official record
Conditions
Marginal Ulcer, Chronic Ulcer Disease, Persistent Ulcer Disease, Recurrent Ulcer Disease, Late Morbidity After Gastric Bypass
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational

Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit

NCT06225167
View directory record Official record
Conditions
Stress Ulcer
Interventions
To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

NCT00001191
View directory record Official record
Conditions
Gastrinoma, Zollinger Ellison Syndrome
Interventions
Pantoprazole, Omeprazole
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 5:45 AM EDT